Lymphoma

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

No new safety signals were observed with liso-cel, with the therapy showing low rates of severe cytokine release syndrome and neurologic events.

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Patients with R/R DLBCL given polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin had an OS of 19.5 months.

Tetiana Skrypets, MD, highlighted that older adults with PTCL may be treated as younger adults if they pass the geriatric assessment.

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.

CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.

Results from the EPCORE NHL-1 trial shared at the 2025 ASCO Annual Meeting found positive responses in patients with relapsed/refractory large B-cell lymphoma.

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.

At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL.

Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.

The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.